Sight Sciences, Inc.

What they do

Sight Sciences develops and sells interventional medical devices for ophthalmology, primarily in the U.S. Its Interventional Glaucoma segment includes the OMNI and SION surgical systems for minimally invasive glaucoma surgery, and its Interventional Dry Eye segment includes the TearCare system for dry eye disease. The company markets directly to eye care professionals and generates revenue from product sales.

Revenue drivers

• Interventional Glaucoma (IG) — The largest segment, generating $20.7M in Q2 2026 (8% YoY growth), driven by increased procedure volumes from products like OMNI and SION.
• Interventional Dry Eye (IDE) — A smaller but fast-growing segment, with $2.7M in Q2 2026 (704% YoY growth) due to higher volumes and average selling prices, plus expanded reimbursement coverage for TearCare.

Recent performance

In Q2 2026, revenue was $23.4M, up 20% YoY, with IG revenue at $20.7M and IDE at $2.7M. Gross margin was 91%, including a $1.4M tariff refund benefit; excluding that, 86% versus 85% a year ago. Cash and equivalents were $79.8M at June 30, 2026, with $5.2M cash used in the quarter, including a $5.4M litigation success fee partially offset by $1.6M tariff refunds. Full-year 2025 revenue was $77.4M with a net loss of $38.4M.

Strategy

The company is focused on expanding reimbursement coverage for both segments, as evidenced by IDE patient lives growing from 10.4M to 14.5M and Aetna covering IG procedures retroactively to July 14, 2026. It plans to leverage the newly cleared OMNI Ultra with TruSync Plus technology to enhance procedural control and efficiency. Management emphasizes disciplined operating expense and cash management, aiming to reduce cash burn while scaling via new product clearances and coverage wins.

Risks

• Ongoing losses — The company has a history of net losses and an accumulated deficit of $384.7M as of December 31, 2025, and expects to continue incurring losses.
• Reimbursement dependency — Revenue growth is heavily reliant on obtaining and maintaining favorable reimbursement for its products; any adverse coverage decisions could hurt sales.
• Litigation costs — Ongoing IP litigation with Alcon Inc. and affiliates could result in significant legal expenses and potential adverse outcomes.
• Competition — The company faces competition from existing competitors and new market entrants in both glaucoma and dry eye device markets.

Outlook

Management raised full-year 2026 revenue guidance and reduced adjusted operating expense guidance, citing year-to-date growth and momentum. They expect continued growth in both IG and IDE, with the IDE segment growing sequentially and aided by expanded reimbursement. Cash usage is expected to improve further, excluding one-time items, based on disciplined expense management.